HNC 1058
Alternative Names: HNC-1058Latest Information Update: 05 Apr 2024
At a glance
- Originator Guangzhou Henovcom Bioscience
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 08 Mar 2024 Guangzhou Henovcom Bioscience completes phase-I trial in Idiopathic pulmonary fibrosis (In volunteers) in USA (PO) (NCT05803850)
- 28 Mar 2023 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In volunteers) in USA (PO) (NCT05803850)